Alessandro Franceschi

Dr. Alessandro Franceschi

polytechnic university of marche
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2020 in Vision
Verified
Journal Article
Open access
PDF file
MNMichele Nicolai
Michele Nicolai
NLNicola Lassandro
Nicola Lassandro
AFAlessandro Franceschi
Alessandro Franceschi
ARAlessandro Rosati
Alessandro Rosati
STSerena De Turris
Serena De Turris
CMCesare Mariotti
Cesare Mariotti
Silicone oil represents the main choice for intraocular tamponade in cases of complicated retinal detachment surgery. The intraocular pressure of an eye filled with silicone oil could increase, driven by a variety of different forces, according to several mechanisms. Two main conditions have been highlighted, depending on the onset: early hypertension or late glaucoma. The different types of silicone oils and their physico-chemical properties are varied and may play a role in the determination of intraocular pressure rise. The current body of literature allows for the illustration and categorization of the incidence and risk factors, as well as the pathogenesis and the management of the early postoperative hypertension subtended by an open- and closed-angle, along with the late onset silicone oil-induced glaucoma. Understanding the leading actors on the stage of ocular pressure elevation concurrently with silicone oil application for retinal surgery could help in guiding the timely and appropriate course of treatment.

6 October 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MNMichele Nicolai
Michele Nicolai
AFAlessandro Franceschi
Alessandro Franceschi
STSerena De Turris
Serena De Turris
ARAlessandro Rosati
Alessandro Rosati
VPVittorio Pirani
Vittorio Pirani
CMCesare Mariotti
Cesare Mariotti
Purpose: To investigate papillary microvascular changes in patients affected by macular edema due to Central Retinal Vein Occlusions (CRVO) after anti-Vascular Endothelial Growth Factor (VEGF) therapy. Methods: Prospective analysis of papillary and peripapillary vessel density (VD) changes in 18 eyes of 18 hypertensive patients affected by CRVO before and after the loading-phase of intravitreal Ranibizumab (IVR) injections. Data were quantitatively measured by optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) before as well as 1 month and 4 months after injections. The correlation between post-treatment best-corrected visual acuity (BCVA) and changes in the retinal microvasculature evaluated by OCTA was assessed. Results: 18 eyes of 18 consecutive patients with a known history of arterial hypertension and affected by an acute CRVO episode were enrolled. Central macular thickness (CMT) was significantly reduced after IVR injections (p < 0.001), while mean BCVA improved from 0.70 ± 0.26 logarithm of the minimal angle of resolution (logMAR) units at baseline to 0.25 ± 0.18 logMAR units after 4 months (p < 0.001). VD inside disc and peripapillary significantly increased (p < 0.001 and p = 0.01, respectively) after treatment. Conclusions: OCTA showed VD increase in the papillary area in patients affected by CRVO after anti-VEGF therapy. This area could represent a new region of interest to study microvasculature changes concomitant with severe macular edema.

5 September 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VPVittorio Pirani
Vittorio Pirani
PPPaolo Pelliccioni
Paolo Pelliccioni
STSerena De Turris
Serena De Turris
ARAlessandro Rosati
Alessandro Rosati
AFAlessandro Franceschi
Alessandro Franceschi
CMCesare Mariotti
Cesare Mariotti
Background: Syphilis, tuberculosis and toxoplasmosis are major infectious diseases worldwide; all of them are multisystem pathologies and share a possible ocular involvement. In this context, a fundamental help for the definitive diagnosis is provided by the ophthalmologist, through clinical evaluation and with the aid of a multimodal imaging examination. Methods: We hereby describe selected cases who came to our attention and were visited in our eye clinic. In all clinics, the use of retinal and optic disc multimodal imaging during ophthalmological evaluation allowed to make a diagnosis of an infectious disease. Results: In our tertiary referral center more than 60 patients with syphilis, tuberculosis and toxoplasmosis have been evaluated in the last two years: In 60% of cases the ophthalmological evaluation was secondary to a previous diagnosis of an infectious disease, while in the remaining cases the ophthalmologist, with the help of a multimodal imaging examination and clinical evaluation, represented the physician who leads to the diagnosis. Conclusion: Our results confirm how in these life-threatening pathologies a prompt diagnosis is mandatory and may benefit from a multidisciplinary and multimodal imaging approach, especially during ophthalmological evaluation.

16 August 2020 in Vision
Verified
Journal Article
Open access
PDF file
MNMichele Nicolai
Michele Nicolai
AFAlessandro Franceschi
Alessandro Franceschi
PPPaolo Pelliccioni
Paolo Pelliccioni
VPVittorio Pirani
Vittorio Pirani
CMCesare Mariotti
Cesare Mariotti
The EX-PRESS glaucoma filtration device appears to be an effective addition to our options to treat refractory glaucoma. The possibility to create a sclerostomy without tissue excision provides a safe and reliable outflow pathway for aqueous that is standard in size, reducing much of the variability associated with a surgical procedure. Prospective randomized studies comparing EX-PRESS implantation with trabeculectomy show encouraging results. However, complications usually encountered in filtration surgery have been reported, and EX-PRESS implantation can also lead to specific device-related complications. This article reviews the most common complications associated with this procedure.

22 July 2015 in European Journal of Orthopaedic Surgery & Traumatology
Verified
Journal Article
Closed access
PDF file
MVMatteo Vitali
Matteo Vitali
APAlberto Pedretti
Alberto Pedretti
NRNadim Naim Rodriguez
Nadim Naim Rodriguez
AFAlessandro Franceschi
Alessandro Franceschi
GFGianfranco Fraschini
Gianfranco Fraschini

13 February 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
VPVittorio Pirani
Vittorio Pirani
PPPaolo Pelliccioni
Paolo Pelliccioni
STSerena De Turris
Serena De Turris
ARAlessandro Rosati
Alessandro Rosati
AFAlessandro Franceschi
Alessandro Franceschi
CMCesare Mariotti
Cesare Mariotti
Background: Non-infectious uveitis represents a leading cause of visual impairment, and inflammation control represents a major priority in tackling visual acuity loss due to complications such as macular edema; different immunomodulatory drugs are currently being used, including anti-TNF-alpha Adalimumab. Methods: This was a monocentric observational study of 18 eyes of 18 patients with non-infectious uveitis treated with Adalimumab. The primary endpoint was the control of ocular inflammation. The secondary endpoints included the study of macular and choroidal thickness and architecture, visual acuity, changes in other treatments, and adverse effects. Results: Ocular inflammation was controlled at 12 months for 83.3% of patients. Central macular thickness improved from a median of 229.75 µm at baseline to 213 µm at 12 months, while choroidal thickness decreased by 11.54% at the end of the follow-up. A reduction of vasculitis on fluorescein angiography and of hyperreflective spots on optical coherence tomography was noted. Visual acuity also improved from 0.51 (logMAR) before treatment to 0.24 at more than 12 months (p = 0.01). A total of 11.1% of patients experienced side effects. Conclusion: Our study confirms the efficacy of adalimumab for the control of ocular inflammation, visual acuity preservation, and for corticosteroid sparing.